Pleural Mesothelioma
39
12
13
12
Key Insights
Highlights
Success Rate
60% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 87/100
20.5%
8 terminated out of 39 trials
60.0%
-26.6% vs benchmark
5%
2 trials in Phase 3/4
50%
6 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 12 completed trials
Clinical Trials (39)
Mesothelioma Early Detection by VOCs
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO
Evaluation of Skin Tests in Biotherapy Allergies
A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
From Presentation to Diagnosis: Patterns of Pleural Effusion
INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP)
DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)
TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study
A Beta-only IL-2 ImmunoTherapY Study
The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma
Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma
A Study of MT027 in Patients with Pleural Malignant Tumors
A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma
Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma
Evaluation of Response by FLT PET in Mesothelioma